Cargando…

Establishment of lactate-metabolism-related signature to predict prognosis and immunotherapy response in patients with colon adenocarcinoma

The outcome of colon adenocarcinoma (COAD) patients remains dismal, and lactate metabolism has been characterized to promote tumor development and immune evasion. Based on the above background, it is worthwhile to explore novel prognostic and therapeutic biomarkers for COAD patients from the aspect...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Zhengrong, Chai, Yongjie, Li, Qi, Lin, Xuan, He, Qingfang, Xiong, Qiusheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515658/
https://www.ncbi.nlm.nih.gov/pubmed/36185199
http://dx.doi.org/10.3389/fonc.2022.958221
_version_ 1784798533125144576
author Zou, Zhengrong
Chai, Yongjie
Li, Qi
Lin, Xuan
He, Qingfang
Xiong, Qiusheng
author_facet Zou, Zhengrong
Chai, Yongjie
Li, Qi
Lin, Xuan
He, Qingfang
Xiong, Qiusheng
author_sort Zou, Zhengrong
collection PubMed
description The outcome of colon adenocarcinoma (COAD) patients remains dismal, and lactate metabolism has been characterized to promote tumor development and immune evasion. Based on the above background, it is worthwhile to explore novel prognostic and therapeutic biomarkers for COAD patients from the aspect of lactate metabolism. Above all, 228 available lactate-metabolism-related genes (LMRGs) were acquired, and the landscape of copy number variation and the expression difference of mRNA levels between colon normal and tumor samples were investigated among these LMRGs. Importantly, eight overall survival (OS)-involved LMRGs were then distinguished by means of univariate Cox regression analysis in both GSE40967 and TCGA-COAD data sets. Subsequently, prognostic risk scores were established, integrating seven OS-related LMRGs by LASSO Cox regression analysis in the GSE40967 set, and then verified in the TCGA-COAD cohort. From the comprehensive analyses, COAD patients with high risk had comparatively more inferior survival probability in all populations of the study, and they tended to have more severe clinicopathological features with the risk score increasing. Moreover, by integrating age, AJCC T and pathological stage, and risk score, we constructed a prognostic nomogram that demonstrated great prediction effectiveness for OS of COAD patients. Furthermore, the potential effect of various risk score on tumor immune was assessed from enrichment of immune-related pathways, tumor-infiltrating immune cells, and expression levels of immune checkpoints separately. We could draw a conclusion that COAD patients with higher lactate-metabolism-related risk scores may acquire an immunosuppressive tumor microenvironment, which subsequently led to immune escapes and poor prognoses. Conclusively, all findings in the present study illustrate a great prognostic value of the lactate-metabolism-related risk signature, providing more in-depth insights into the indispensable function of lactate metabolism in prognosis and tumor immunity of COAD.
format Online
Article
Text
id pubmed-9515658
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95156582022-09-29 Establishment of lactate-metabolism-related signature to predict prognosis and immunotherapy response in patients with colon adenocarcinoma Zou, Zhengrong Chai, Yongjie Li, Qi Lin, Xuan He, Qingfang Xiong, Qiusheng Front Oncol Oncology The outcome of colon adenocarcinoma (COAD) patients remains dismal, and lactate metabolism has been characterized to promote tumor development and immune evasion. Based on the above background, it is worthwhile to explore novel prognostic and therapeutic biomarkers for COAD patients from the aspect of lactate metabolism. Above all, 228 available lactate-metabolism-related genes (LMRGs) were acquired, and the landscape of copy number variation and the expression difference of mRNA levels between colon normal and tumor samples were investigated among these LMRGs. Importantly, eight overall survival (OS)-involved LMRGs were then distinguished by means of univariate Cox regression analysis in both GSE40967 and TCGA-COAD data sets. Subsequently, prognostic risk scores were established, integrating seven OS-related LMRGs by LASSO Cox regression analysis in the GSE40967 set, and then verified in the TCGA-COAD cohort. From the comprehensive analyses, COAD patients with high risk had comparatively more inferior survival probability in all populations of the study, and they tended to have more severe clinicopathological features with the risk score increasing. Moreover, by integrating age, AJCC T and pathological stage, and risk score, we constructed a prognostic nomogram that demonstrated great prediction effectiveness for OS of COAD patients. Furthermore, the potential effect of various risk score on tumor immune was assessed from enrichment of immune-related pathways, tumor-infiltrating immune cells, and expression levels of immune checkpoints separately. We could draw a conclusion that COAD patients with higher lactate-metabolism-related risk scores may acquire an immunosuppressive tumor microenvironment, which subsequently led to immune escapes and poor prognoses. Conclusively, all findings in the present study illustrate a great prognostic value of the lactate-metabolism-related risk signature, providing more in-depth insights into the indispensable function of lactate metabolism in prognosis and tumor immunity of COAD. Frontiers Media S.A. 2022-09-14 /pmc/articles/PMC9515658/ /pubmed/36185199 http://dx.doi.org/10.3389/fonc.2022.958221 Text en Copyright © 2022 Zou, Chai, Li, Lin, He and Xiong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zou, Zhengrong
Chai, Yongjie
Li, Qi
Lin, Xuan
He, Qingfang
Xiong, Qiusheng
Establishment of lactate-metabolism-related signature to predict prognosis and immunotherapy response in patients with colon adenocarcinoma
title Establishment of lactate-metabolism-related signature to predict prognosis and immunotherapy response in patients with colon adenocarcinoma
title_full Establishment of lactate-metabolism-related signature to predict prognosis and immunotherapy response in patients with colon adenocarcinoma
title_fullStr Establishment of lactate-metabolism-related signature to predict prognosis and immunotherapy response in patients with colon adenocarcinoma
title_full_unstemmed Establishment of lactate-metabolism-related signature to predict prognosis and immunotherapy response in patients with colon adenocarcinoma
title_short Establishment of lactate-metabolism-related signature to predict prognosis and immunotherapy response in patients with colon adenocarcinoma
title_sort establishment of lactate-metabolism-related signature to predict prognosis and immunotherapy response in patients with colon adenocarcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515658/
https://www.ncbi.nlm.nih.gov/pubmed/36185199
http://dx.doi.org/10.3389/fonc.2022.958221
work_keys_str_mv AT zouzhengrong establishmentoflactatemetabolismrelatedsignaturetopredictprognosisandimmunotherapyresponseinpatientswithcolonadenocarcinoma
AT chaiyongjie establishmentoflactatemetabolismrelatedsignaturetopredictprognosisandimmunotherapyresponseinpatientswithcolonadenocarcinoma
AT liqi establishmentoflactatemetabolismrelatedsignaturetopredictprognosisandimmunotherapyresponseinpatientswithcolonadenocarcinoma
AT linxuan establishmentoflactatemetabolismrelatedsignaturetopredictprognosisandimmunotherapyresponseinpatientswithcolonadenocarcinoma
AT heqingfang establishmentoflactatemetabolismrelatedsignaturetopredictprognosisandimmunotherapyresponseinpatientswithcolonadenocarcinoma
AT xiongqiusheng establishmentoflactatemetabolismrelatedsignaturetopredictprognosisandimmunotherapyresponseinpatientswithcolonadenocarcinoma